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Abstract: Renealmia alpinia (Rottb.) MAAS, obtained by micropropagation (in vitro) and 
wild forms have previously been shown to inhibit some toxic activities of Bothrops asper 
snake venom if preincubated before injection. In this study, assays were performed in a 
murine model in which extracts were administered for three days before venom injection.  
R. alpinia extracts inhibited lethal activity of B. asper venom injected by intraperitoneal 
route. Median Effective Dose (ED50) values were 36.6 ± 3.2 mg/kg and 31.7 ± 5.4 mg/kg  
(p > 0.05) for R. alpinia wild and in vitro extracts, respectively. At a dose of 75 mg/kg, both 
extracts totally inhibited the lethal activity of the venom. Moreover, this dose prolonged 
survival time of mice receiving a lethal dose of venom by the intravenous route. At 75 mg/kg, 
both extracts of R. alpinia reduced the extent of venom-induced pulmonary hemorrhage by 
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48.0% (in vitro extract) and 34.7% (wild extract), in agreement with histological 
observations of lung tissue. R. alpinia extracts also inhibited hemorrhage in heart and 
kidneys, as evidenced by a decrease in mg of hemoglobin/g of organ. These results suggest 
the possibility of using R. alpinia as a prophylactic agent in snakebite, a hypothesis that 
needs to be further explored. 
Keywords: Renealmia alpinia; snake venoms; metalloproteinase; serine proteinase;  
anti-venom activity; micropropagated plants 
 
1. Introduction 
Envenomation by snakebites is a relevant public health issue in many regions of the world, 
particularly in tropical and subtropical countries of Africa, Asia, Latin America and Oceania [1]. In the 
case of snakes of the family Viperidae, which inflict the vast majority of accidents in the Americas,  
the pathophysiology of envenomation includes both local and systemic manifestations associated with 
hemorrhage, necrosis, edema, hypovolemia, nephrotoxicity, coagulopathy and cardiovascular shock [2]. 
This complex clinical picture is the result of the action of various venom components, predominantly 
proteinases metallo and serine proteinases, phospholipases A2, C-type lectin-like proteins, and other 
minor components [3]. 
Bothrops asper is responsible for 50%–80% of snakebites, and 60%–90% of deaths secondary to 
snakebites in Central America and northern South America [4]. Envenoming by this species induces 
marked local tissue damage that includes pain, edema, hemorrhage, blisters, dermonecrosis and 
myonecrosis [4,5]. On the other hand, the clinical manifestations of systemic alterations induced by  
B. asper venom include bleeding, coagulopathy, hypotension, hemodynamic alterations, pulmonary 
edema, and acute renal failure. In addition, other less common effects might occur, such as intravascular 
hemolysis, acute myocardial damage and, in severe cases not treated timely with antivenom, multiple 
organ failure and death [4,5]. 
The therapy for snakebite envenomations has been based on the intravenous administration of 
antivenoms [6]. However, it has been demonstrated that current therapy for snakebite has a limited 
efficacy against the local tissue damaging activities of venoms [7]. In addition, antivenoms are not 
available in all rural and distant places where most snakebites occur, a feature that has promoted the use 
of traditional medicine practices and delays the administration of specific treatment [8]. Moreover, some 
antivenoms induce early adverse reactions (EARs) in a high proportion of patients and some of them 
require cold chain for storage and transportation, a difficult task in many rural areas [8]. Thus, it is 
important to search for novel venom inhibitors, either synthetic or natural, that would complement the 
action of antivenoms. 
Medicinal plants represent a vital source of novel bioactive compounds with several pharmacological 
activities that have contributed directly in the search of alternatives against ophidian envenomation or as 
a complement to conventional antivenom therapy [9]. Renealmia alpinia (Rottb.) MAAS (Zingiberaceae), 
known as guaiporé, pintura negra, jazmín de monte, matandrea o achira de monte [10–12], has been 
used in the traditional medicine of Colombia to treat snakebites [13]. In addition, this plant has been 
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effective in experimental models to neutralize edema-forming, hemorrhagic, lethal, and defibrinating 
activities of Bothrops asper venom when incubated with the venom prior to injection [14–16]. In order 
to increase the productivity and homogeneity of R. alpinia extract, our group carried out a study with 
micropropagation of this plant, to obtain enough plant material, which would not be possible to achieve 
with traditional methods [17]. Moreover, extracts from roots and leaves of this in vitro grown plant 
inhibited the proteolytic, coagulant, and indirect-hemolytic activities of B. asper venom [18]. 
Additionally, R. alpinia rhizomes extract neutralized the edema-forming activity of B. asper venom [14]. 
On the other hand, Gomez-Betancur et al. [19] isolated a flavanone (pinostrobin) from the leaf extract 
of R. alpinia, this compound inhibited the carrageenan-induced edema. 
One scenario that has received little attention regarding the potential of natural products as antagonists 
of venom components is the administration of extracts prior to envenomation, as a model of ingesting 
plant extracts in conditions of high risk of snake bites. In this work, extracts of R. alpinia obtained by 
micropropagation (in vitro) and wild forms were tested and compared for their capacity to inhibit lethal 
and hemorrhagic activities of B. asper venom. Results indicate that administration of these extracts 
during three days before venom injection exerts a significant protection in mice. 
2. Results 
2.1. Inhibition of Lethal Activity 
R. alpinia extracts inhibited, in a dose-dependent manner, the lethal activity induced by 1.5 × LD50sB. 
asper venom (Figure 1). Both extracts totally inhibited the lethal activity of B. asper venom at 75 mg/kg. 
Moreover, at all doses used, R. alpinia wild and in vitro extracts protected mice in a comparable way  
(p > 0.05). ED50 values were 36.6 ± 3.2 mg/kg and 31.7 ± 5.4 mg/kg (p > 0.05) for R. alpinia wild and 
in vitro extracts, respectively. R. alpinia extracts were not lethal in mice at all doses tested. 
 
Figure 1. Inhibition of lethal activity induced by B. asper venom. During three days, groups 
of five mice received an intraperitoneal (i.p.) injection of either R. alpinia wild or  
in vitro extracts. At the fourth day, all groups were injected by i.p. route with of  
1.5 × LD50s B. asper venom, and deaths were recorded during 48 h. Results are shown as 
mean ± SEM, n = 5. 
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On the other hand, in the assay involving pretreatment with the extracts followed by intravenous (i.v.) 
injection of a lethal dose of venom, there was no protection at 24 h, since all envenomed mice died. 
However, there was a notorious delay in the time of death in mice receiving the extracts. Mice injected 
with venom alone survived only 2.25 h. In contrast, animals receiving the extracts (75 mg/kg) and then 
venom survived 5.17 h (in vitro extract) and 3.83 h (wild extract) (p < 0.01). 
2.2. Inhibition of Pulmonary Hemorrhage 
The minimum pulmonary hemorrhagic dose (MPHD) of B. asper venom was 30 μg. In the inhibition 
assay we decided to test a dose of 40 μg venom, in order to provoke a conspicuous effect. B. asper venom 
induced a total hemorrhagic diameter of 7.5 ± 0.25 mm, when adding all the hemorrhagic spots in the 
surface of the lungs. In mice treated with 75 mg/kg of extracts, the sums of diameters of hemorrhagic 
lesions were 3.9 ± 0.19 mm and 4.9 ± 0.23, for R. alpinia in vitro and wild extracts, respectively  
(p < 0.05 when compared with venom alone). This represents an inhibition of pulmonary hemorrhage of 
48% and 35%, respectively. 
2.3. Histological Analysis 
Histological analysis revealed widespread hemorrhage and congestion in pulmonary tissue of mice 
injected with venom alone with abundant erythrocytes in the alveolar spaces (Figure 2A). In contrast, 
histological observations of reddish areas in lungs of mice treated with R. alpinia extracts before 
envenomation showed less extravasation than in sections from mice injected with venom alone  
(Figure 2B,C). 
 
Figure 2. Light micrographs of sections of pulmonary tissue from mice injected i.v. with  
40 μg of B. asper venom (A) or pre-treated with 75 mg/kg of R. alpinia in vitro extract (B), 
or wild extract (C), and then injected with venom. Overt hemorrhage and congestion is 
evident in (A), with erythrocytes present in the alveolar spaces (arrows), whereas the extent 
of extravasation is much lower in samples from mice pretreated with the plant extracts and 
then receiving venom (B and C). Bar corresponds to 100 μm. 
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2.4. Inhibition of Venom-Induced Hemorrhage in Heart and Kidneys 
We also evaluated the inhibition of venom-induced systemic hemorrhage by quantifying mg of 
hemoglobin/g of organ in homogenates of kidneys and heart after subcutaneous (s.c.) injection of venom 
and pretreatment with the extracts. In both cases, venom induced its highest effect 6 h after injection.  
At all times, mice treated with either antivenom, in vitro or wild extracts showed a partial inhibition of 
hemorrhage, as compared with mice injected with venom alone (p < 0.05) (Figure 3A), although there 
were differences in the inhibitory activity of these three treatments. Regarding inhibition of hemorrhage in 
the kidneys, at 1 and 6 h, antivenom and the two plant extracts induced a significant reduction of this 
effect, with differences between treatments (p < 0.05) (Figure 3B). However, at 24 h, only in vitro extract 
exhibited significant differences when compared with venom (p < 0.05). The quantification of 
hemoglobin in heart and kidneys, after control treatments with in vitro and wild extracts alone was 
similar to that induced by PBS alone (p > 0.05). 
 
Figure 3. Inhibition, by plant extracts, of venom-induced hemorrhage in heart and kidneys. 
Mice were pre-treated with R. alpinia in vitro or wild extracts, and then injected with  
B. asper venom by the s.c. route. At 1, 6 and 24 h, mice were sacrificed, heart (A) and 
kidneys (B) were dissected, and hemoglobin (mg/g of organ) was quantified and compared 
with organs of animals that received venom alone or venom + antivenom. Results are shown 
as mean ± SEM, n = 4. 
3. Discussion 
Our observations show that pretreatment of mice with in vitro and wild extracts of the plant  
R. alpinia protects against toxicity, i.e., lethality and systemic hemorrhage, induced by the venom of  
B. asper. These findings complement previous observations showing the ability of extracts from this 
plant to inhibit toxic and enzymatic activities of this venom [14,16–20]. 
Lethality is the most important consequence of snakebite envenomation. The mechanisms of  
venom-induced lethality vary depending on the type of venom. In the case of the majority of viperid 
venoms, it is likely the consequence of the combined action of several toxins, and of endogenous 
deleterious mechanisms elicited by the action of venom components in the organism. Gutierrez et al. [5] 
hypothesized that B. asper venom lethal activity is likely to depend on several mechanisms. In the case 
of i.v. injection, the following components are likely to play a role: (a) the capacity of the Basparin A,  
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a procoagulant P-III SVMPs, to provoke the formation of abundant thrombi in pulmonary blood vessels, 
probably as a consequence of thrombin generation [21]. (b) The profuse hemorrhage in the lungs of mice 
presented rapidly after i.v. injection of BaH4, a purified hemorrhagic P-III SVMP [22]. This agrees with 
other studies with various hemorrhagic P-III snake venom metalloproteinases (SVMPs), from other 
viperid venoms, which provokes rapid systemic bleeding [23–25]. (c) The ability of asperase [26],  
a thrombin-like serine proteinase, to induce an intravascular thrombosis upon i.v. injection. On the other 
hand, other, as yet unidentified, toxins are likely to play a role in lethality when the venom is 
administered by the i.p. route [5]. It might be that a number of venom components, which by themselves 
are of low toxicity, contribute to the overall toxicity of the venom by synergistic and additive effects 
when acting in combination with other toxins in the crude venom. 
Pretreatment of mice with extracts of R. alpinia by the i.p. route resulted in a protection from the 
lethal effect of B. asper venom when injected i.p. at a dose corresponding to 1.5 × LD50s. Nevertheless, 
the inhibitory potential of these extracts was more limited when venom was administered by the i.v. 
route. This difference in inhibitory potential might have two explanations: (a) it might be that secondary 
metabolites of the extract, when injected i.p., accumulate in the peritoneal cavity. Hence, when venom 
is injected by this route, these metabolites would directly react with the venom, thus facilitating 
inhibition. Such direct interaction between venom and extract would occur to a much lower extent in the 
bloodstream after i.v. injection of venom. (b) It might be that the toxins responsible for lethality differ 
depending on the route. When administered i.v., it is highly likely that coagulant and procoagulant toxins 
play a protagonic role in lethality, through intravascular thrombosis, whereas such components are not 
likely to play a key role when injected i.p., owing to their slow systemic absorption. Thus, the rapid 
inhibition of these coagulant components in the circulation is very difficult to achieve by the plant extracts. 
Systemic hemorrhage is one of the most serious consequences of envenomations by B. asper, 
resulting in severe blood loss leading to cardiovascular collapse [2,4]. Systemic hemorrhage is due to 
the action of hemorrhagic metalloproteinases, particularly P-III SVMPs which present various properties 
that make them more hemorrhagic than P-I SVMPs, such as: (a) presence of exosites in the disintegrin-like 
and cysteine-rich domains, enabling them to target key sites in the microvasculature [27,28].  
(b) The ability to inhibit platelet aggregation [29]. (c) Resistance to the inhibitory action of  
α2-macroglobulin [28,30]. In addition, the effects of serine proteinases and SVMPs in hemostasis further 
contribute to systemic bleeding [5,31]. 
R. alpinia extracts partially inhibited venom-induced hemorrhage in lungs, kidneys and heart.  
These findings suggest that the extracts of this plant contain secondary metabolites able to interact, and 
inhibit, hemorrhagic SVMPs. In a recent study, Patiño et al. [20] demonstrated that R. alpinia in vitro 
and wild extracts inhibited hemorrhage, defibrin(ogen)ating, proteolytic, edema-forming, among other 
activities of a SVMP and thrombin-like enzymes. In that study, terpenoids, flavonoids, tannins, and 
coumarins were detected in both R. alpinia extracts. Terpenoids and coumarins have been previously 
reported in this species [18,32–34]. Some of these compounds have been reported as metal  
chelators [35,36]; therefore, they could chelate Zn2+, which is required by SVMPs for their catalytic 
mechanism. In the same way, other compounds such as terpenoids have been reported as SVMPs 
inhibitors [37], whereas coumarins have been described as serine proteinase and matrix metalloproteinase 
(MMP) inhibitors [38,39]. Thus, extracts of R. alpinia contain several types of secondary metabolites, 
which could mediate the inhibitory effect on hemorrhage observed in this work. The identification of 
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these inhibitory compounds, and the study of their mechanism of inhibition, awaits further investigations. 
An interesting alternative possibility to explain our findings has to do with the induction of physiological 
changes in mice, due to the exposure to the extracts prior to venom injection, which may stimulate 
endogenous mechanisms involving resistance to the action of venoms. 
Most studies on the effects of plant extracts on snake venoms have used a methodology based on the 
incubation of venom and the extract before testing in vivo or in vitro pharmacological models. Hereby 
we have explored an alternative model to assess inhibition, i.e., by administration of the extract in mice during 
several days before envenomation. This method pretends to model a scenario in which extracts are ingested 
in situations of high risk of snakebite, thus providing protection before envenomation. The results obtained, 
together with previous observations on the lack of acute toxicity of extracts of R. alpinia [40], give support 
to this alternative of prophylactic use of plant extracts, a hypothesis that requires further studies using 
other experimental models and evaluating the chronic toxicity of these extracts. 
4. Experimental Section 
4.1. Venom 
Bothrops asper venom was obtained by manual extraction of 20 specimens from the northwest region 
of Colombia (Antioquia and Chocó states), which are maintained in captivity at the animal house of the 
Universidad de Antioquia (Medellin, Colombia). Then, venom was centrifuged at 800 g for 15 min,  
and the supernatants were lyophilized and stored at −20 °C until use. 
4.2. Animals 
Swiss Webster mice (18–20 g body weight) were used for in vivo assays. All experiments were 
conducted in accordance with the guidelines of the Universidad de Antioquia Ethics Committee 
(expedient number 53, 16 June 2009) (Medellín, Colombia). 
4.3. Plant Material and Preparation of Extracts of R. alpinia 
The leaves of R. alpinia were collected in the wild of plants grown on the campus of the University 
of Antioquia, (1.454 meters above sea level (m.a.s.l.) voucher 107316, registration number 6456 RF. On the 
other hand, R. alpinia in vitro was obtained by the method described by Alarcón et al. [17]. Whole plant was 
used to prepare the extract. Leaves and whole plants from R. alpinia wild and in vitro, respectively, were 
dried at 37 °C. Then, dried and milled plant material was extracted overnight with 90% ethanol,  
three times. The resultant ethanol extract was concentrated at a temperature below 40 °C to a semisolid 
paste using a rotary evaporator (BÜCHI–124 Flawil, Switzerland). Finally, extracts were lyophilized and 
frozen until their use. 
4.4. Inhibition of Lethal Activity of B. asper Venom by R. alpinia Extracts 
For three days, groups of five mice received an i.p. injection of either R. alpinia wild or in vitro extract 
(12.5, 25.0, 37.5, 50.0, 62.5 and 75.0 mg/kg in 200 μL of 0.12 M NaCl, 0.04 M phosphate, pH 7.2 (PBS) 
containing 0.05% Tween. On the fourth day, all groups were injected by the i.p. route with 70 μg of  
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B. asper venom in 100 μL PBS (corresponding to 1.5 × LD50). Control groups received either venom 
alone or PBS with 0.05% Tween alone. Deaths were registered within 48 h. The Median Effective Doses 
(ED50) of both extracts were calculated by Probit analysis [41]. In addition, some assays were carried 
out with i.p. injection of extracts for three days, as described, followed by the intravenous (i.v.) injection, 
via the tail vein, of 1.5 × lethal doses (105 µg) of venom on the fourth day. In this case, deaths were 
registered within 24 h. 
4.5. Determination of the Minimum Pulmonary Hemorrhagic Dose 
Groups of four mice (18–20 g) were injected intravenously (i.v.), via the tail vein, with various doses 
of B. asper venom dissolved in 100 μL PBS. Two and a half hours after injection, mice were sacrificed 
by CO2 inhalation. The lungs were immediately dissected out and the presence of hemorrhagic spots was 
assessed. The MPHD is defined as the minimum dose of venom, which induced visible hemorrhagic 
spots in all mice injected [25]. 
4.6. Inhibition of Venom-Induced Pulmonary Hemorrhage 
For three days, groups of eight mice received an intraperitoneal (i.p.) injection of 75 mg/kg of either 
R. alpinia wild or in vitro extracts. On the fourth day, all groups were injected by the i.v. route, in the 
tail vein, with 40 μg of venom. Two and a half hours after venom injection, mice were sacrificed by CO2 
inhalation. The lungs were immediately dissected out and the presence of hemorrhagic spots was 
assessed. Control groups received either venom alone or PBS with 0.05% Tween alone. The diameters  
of the hemorrhagic spots were quantified and the hemorrhagic activity was expressed as the sum of 
hemorrhagic diameters of all hemorrhagic spots; inhibition was then expressed as percentage of 
reduction of the sum of hemorrhagic diameters. 
4.7. Inhibition of Hemorrhage in Heart and Kidneys 
During three days, groups of four mice received an intraperitoneal (i.p.) injection of 75 mg/kg of 
either R. alpinia wild or in vitro extracts. On the fourth day, all groups were injected, by the subcutaneous 
(s.c.) route, with 60 μg of venom. In some cases, mice received an i.v. administration of 200 µL of antivenom 
(Antivipmyn Tri®, Batch B-OE-03, expiration date May 2013). One, six and twenty-four hours after 
venom injection, mice were sacrificed by CO2 inhalation. The kidneys and the heart were immediately 
dissected out and briefly washed in PBS to remove external blood. Then, the organs were immersed in 
Drabkin solution for 24 h at 4 °C, protected from the light. Subsequently, tissues were removed from the 
Drabkin solution and, after centrifugation; the absorbance of the supernatant at 540 nm was recorded as a 
quantitative index of hemoglobin present in the tissue. A standard curve of hemoglobin was used to 
determine the amount of hemoglobin released. Control groups received either venom alone or PBS-0.05% 
Tween alone or R. alpinia extracts (75 mg/kg). Results were expressed as mg hemoglobin/g of organ). 
4.8. Histological Studies 
For three days, groups of eight mice received an intraperitoneal (i.p.) injection of 75 mg/kg of either 
R. alpinia wild or in vitro extracts. On the fourth day, all groups were injected by i.v. route with 40 μg 
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of venom. Control groups received either venom alone, PBS–0.05% Tween alone or R. alpinia extracts 
(75 mg/Kg). Two and a half hours after injection, mice were sacrificed by CO2 inhalation. The lungs 
were immediately dissected out. For histological analysis, lungs were placed in 10% formaldehyde and 
processed routinely for embedding in paraffin. Thick sections (4–5 μm) were prepared and stained with 
hematoxylin-eosin for light microscopic observation. 
4.9. Statistical Analysis 
In order to assess the significance of the differences between the mean values of various experimental 
groups in experiments on lethality, two-way ANOVA followed by Bonferroni’s test was applied.  
For the analysis of results of inhibition of the hemorrhagic activity assay, two-way ANOVA followed by 
Bonferroni’s test was applied. In all cases, p < 0.05 was considered significant, and the results are shown 
as mean ± SEM of n indicated in each case. 
5. Conclusions 
In conclusion, our results show that R. alpinia wild and in vitro extracts partially inhibited lethal and 
systemic hemorrhagic activities of B. asper venom, in a model with extract administration before venom 
injection. These results suggest the possibility of using R. alpinia as a prophylactic agent in snakebite,  
a hypothesis that requires further investigations. The similar inhibitory potential of extracts of plants 
propagated in vitro, as compared to wild ones, supports the view that in vitro propagation represents  
a valuable method to obtain extracts for pharmacological and phytochemical studies and for the ex situ 
conservation of genotypes with potential benefits in the development of new inhibitors against snake 
venom toxins. 
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